Bank Of America Corp Satsuma Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.7 - $1.07 $12,824 - $19,603	18,321 Added 100.27%	36,592 $25,000
Q4 2022 Feb 10, 2023	SELL	$0.61 - $5.06 $136 - $1,133	-224 Reduced 1.21%	18,271 $16,000
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $77,494 - $147,035	18,495 New	18,495 $111,000
Q1 2022 May 16, 2022	SELL	$3.78 - $5.32 $16,242 - $22,860	-4,297 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$4.15 - $6.24 $17,832 - $26,813	4,297 New	4,297 $19,000
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $8,639 - $13,644	-1,903 Closed	0 $0
Q2 2021 Sep 13, 2021	BUY	$4.8 - $7.25 $9,134 - $13,796	1,903 New	1,903 $13,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.